Elsevier

Atherosclerosis

Volume 229, Issue 1, July 2013, Pages 174-181
Atherosclerosis

Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis

https://doi.org/10.1016/j.atherosclerosis.2013.04.031Get rights and content

Highlights

  • Tocilizumab in vivo increases LDLc, HDLc, fasting and postprandial triglycerides.

  • Tocilizumab in vitro restores the IL-6 driven over expression of the LDL receptor.

  • Cholesterol synthesis and absorption is unchanged.

  • Lipoprotein changes point towards decreased lipolysis and hepatic remnant uptake.

  • The anti-inflammatory and lipid-elevating effect on net CV risk in RA is unclear.

Abstract

Objectives

Blocking the interleukin-6 pathway by tocilizumab (TCZ) has been associated with changes in the lipoprotein profile, which could adversely impact cardiovascular (CV) risk in patients with rheumatoid arthritis (RA). In the present study, we addressed the effect of TCZ on lipoproteins in both fasting and non-fasting state in RA patients and tested the effect of TCZ on LDL receptor (LDLr) expression in vitro.

Methods

Twenty patients with active RA and an inadequate response to TNF blockers received monthly TCZ intravenously. On week 0, 1 and 6 blood was drawn before and after an oral fat load, the lipid profiles and HDL antioxidative capacity were measured. Effects of TCZ on LDLr expression in transfected HepG2 cells were subjected.

Results

After 6 weeks of TCZ, total cholesterol increased by 22% (4.8 ± 0.9 to 5.9 ± 1.3 mmol/L; p < 0.001), LDLc by 22% (3.0 ± 0.6 to 3.6 ± 0.8 mmol/L; p < 0.001) and HDLc by 17% (1.4 ± 0.4 to 1.7 ± 0.7 mmol/L; p < 0.016). Fasting triglycerides (TG) increased by 48% (1.0 ± 0.4 to 1.4 ± 0.8 mmol/L; p = 0.011), whereas postprandial incremental area under the curve TG increased by 62% (p = 0.002). Lipid changes were unrelated to the change in disease activity or inflammatory markers. No difference in HDL antioxidative capacity was found. In vitro, LDLr expression in cultured liver cells was significantly decreased following TCZ incubation (P < 0.001).

Conclusions

TCZ adversely impacts on both LDLc as well as fasting and postprandial TG in patients with RA. The changes in hepatic LDLr expression following TCZ imply that adverse lipid changes may be a direct hepatic effect of TCZ. The net effect of TCZ on CV-morbidity has to be confirmed in future clinical trials.

Introduction

Rheumatoid arthritis (RA) has been widely acknowledged to increase cardiovascular morbidity and mortality, irrespective of established classical risk factors [1], [2]. Apart from the chronic inflammatory state as a driver of the excess cardiovascular risk [3], additional pro-atherosclerotic pathways including changes in the coagulation and fibrinolytic system and impaired endothelial regenerative capacity have been implicated [4]. Aggressive management of inflammatory activity in RA patients has been projected to reduce this augmented cardiovascular risk [5].

Tocilizumab (TCZ), a humanized monoclonal antibody blocking interleukin-6 (IL-6) signaling by binding both soluble and membrane bound IL-6 receptors (CD126), has been shown to effectively decrease RA disease activity [6], [7]. Upon treatment, TCZ has however been reported to increase total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density cholesterol (HDLc) and triglycerides [8], [9], [10], [11], [12], [13], [14], [15]. It has been put forward that these modifications largely reflect a physiological adaptation following reversal of the chronic inflammatory state, in spite of a lack of studies addressing the underlying mechanisms of the lipid changes following TCZ administration [16]. These changes in lipid profile occur within a week after treatment initiation, which coincides with inhibition of inflammation [17]. The magnitude of the lipid changes associated with TCZ however generally exceed those following treatment with other potent anti-inflammatory regimens such as tumor necrosis factor (TNF) inhibition [18].

Together with the observation that IL-6 may impact on LDLr-mediated removal by the liver [19], we hypothesized that TCZ induced an adverse lipid profile by direct effects on hepatic clearance pathways. Therefore, we investigated the effect of 6 weeks TCZ treatment in RA patients on the fasting and non-fasting lipid profile. Changes in cholesterol synthesis, intestinal absorption, TG lipolysis and clearance, and HDL antioxidative capacity were measured. To validate hepatic changes, the direct effect of TCZ on LDLr expression was tested in HepG2 cells.

Section snippets

Patient selection

Twenty-one patients with RA were recruited from the outpatient clinic of the Academic Medical Center/University of Amsterdam (AMC) and enrolled in the study. The study protocol was approved by the institutional review board at the AMC. Written informed consent was obtained from all participants.

The first four recruited patients received TCZ as part of the ACT-RAY study: a phase IIIb study, designed to evaluate the efficacy and safety of TCZ in patients with RA who do not respond to methotrexate

Results

Of the 21 patients included in the study, one patient dropped out due to abdominal discomfort following oral fat ingestion at the first visit. No serious adverse events were observed during follow-up. After six weeks, TCZ treatment resulted in a substantial decrease in mean CRP from 13.23 (20.66) to 0.17 (0.42) (P < 0.0) (Table 1). Mean DAS28 after 12 weeks decreased from 4.65 (0.73) to 2.83 (1.30) (P < 0.001).

Plasma lipid profiles are depicted in Fig. 1. Following TCZ, TC increased by 22% (4.8

Discussion

TCZ administration in RA patients reduces disease activity as reflected by a reduction in DAS28 score and indices of systemic inflammation. Concomitantly, TCZ is associated with marked increases in LDLc, HDLc as well as in both fasting and postprandial TG levels. Since intestinal cholesterol absorption and whole-body cholesterol synthesis did not change, these changes are likely to reflect decreased clearance. In support, TCZ was found to reduce hepatic LDLr expression, which is expected to

Funding sources

Roche Pharmaceuticals funded this research with an unrestricted grant. Roche Pharmaceuticals had no role in the study design, the collection, analysis and interpretation of the data, and in the writing of the report. Authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. ESGS is supported by a grant from CVON Genius: Generating the best evidence-based pharmaceutical targets for atherosclerosis (GENIUS) (number CVON2011-19).

Acknowledgments and competing interests

We would like to thank all patients, the research nurses and consultant nurses of the Department of Clinical Immunology and Rheumatology, A.W.M. Schimmel, J. Peter and M.E. Doorenspleet for their excellent technical assistance. The LDL receptor promoter plasmid was kindly provided by Prof. Wilhelm Krone (Cologne, Germany).

Prof. Tak has served as consultant to Genentech and Roche, and became an employee of GlaxoSmithKline after completion of this study. Prof. Stroes has received cunsultancy fees

References (46)

  • S. Wallberg-Jonsson et al.

    Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?

    Scand J Rheumatol

    (2004)
  • N. Sattar et al.

    Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

    Circulation

    (2003)
  • R.J. Bisoendial et al.

    The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events

    Semin Thromb Hemost

    (2010)
  • G.G. Ristic et al.

    Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment

    Rheumatology (Oxford)

    (2010)
  • I. Navarro-Millan et al.

    Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor

    Clin Ther

    (2012)
  • M.C. Genovese et al.

    Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

    Arthritis Rheum

    (2008)
  • S.Y. Kawashiri et al.

    Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

    Rheumatol Int

    (2011)
  • R.N. Maini et al.

    Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

    Arthritis Rheum

    (2006)
  • N. Nishimoto et al.

    Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

    Arthritis Rheum

    (2004)
  • N. Nishimoto et al.

    Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

    Ann Rheum Dis

    (2007)
  • N. Nishimoto et al.

    Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

    Mod Rheumatol

    (2009)
  • G. Jones et al.

    Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

    Ann Rheum Dis

    (2010)
  • EMEA

    Scientific discussion for RoActemra

    (23-4-2010)
  • Cited by (87)

    • Hyperlipidemia and rheumatoid arthritis

      2022, Cholesterol: From Chemistry and Biophysics to the Clinic
    • Prospect of 3D bioprinting over cardiac cell therapy and conventional tissue engineering in the treatment of COVID-19 patients with myocardial injury

      2021, Regenerative Therapy
      Citation Excerpt :

      Though tocilizumab inhibits IL-6 and cytokine storm, it causes a type of rare hypertension [47], hypercholesterolemia [73]. Moreover, it is responsible for decreasing hepatic LDL receptor expression and increasing serum LDL cholesterol [75], which can cause atherosclerotic cardiovascular disease. Studies found that exogenous cell transplantation into damaged myocardium can improve myocardial function and vascular supply [76].

    View all citing articles on Scopus
    View full text